181 related articles for article (PubMed ID: 9702205)
21. Synthesis and anti-cancer efficacy of rapid hydrolysed water-soluble paclitaxel pro-drugs.
Ryu BY; Sohn JS; Hess M; Choi SK; Choi JK; Jo BW
J Biomater Sci Polym Ed; 2008; 19(3):311-24. PubMed ID: 18325233
[TBL] [Abstract][Full Text] [Related]
22. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.
Hershberger PA; Yu WD; Modzelewski RA; Rueger RM; Johnson CS; Trump DL
Clin Cancer Res; 2001 Apr; 7(4):1043-51. PubMed ID: 11309356
[TBL] [Abstract][Full Text] [Related]
23. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
Wang Y; Xin D; Liu K; Zhu M; Xiang J
Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
[TBL] [Abstract][Full Text] [Related]
24. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.
Ansell SM; Johnstone SA; Tardi PG; Lo L; Xie S; Shu Y; Harasym TO; Harasym NL; Williams L; Bermudes D; Liboiron BD; Saad W; Prud'homme RK; Mayer LD
J Med Chem; 2008 Jun; 51(11):3288-96. PubMed ID: 18465845
[TBL] [Abstract][Full Text] [Related]
25. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of water-soluble paclitaxel prodrugs.
Feng X; Yuan YJ; Wu JC
Bioorg Med Chem Lett; 2002 Nov; 12(22):3301-3. PubMed ID: 12392737
[TBL] [Abstract][Full Text] [Related]
27. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration.
Lopez RA; Goodman AB; Rhodes M; Blomberg JA; Heller J
Anticancer Drugs; 2007 Sep; 18(8):933-9. PubMed ID: 17667599
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Miller ML; Roller EE; Zhao RY; Leece BA; Ab O; Baloglu E; Goldmacher VS; Chari RV
J Med Chem; 2004 Sep; 47(20):4802-5. PubMed ID: 15369381
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.
Mugabe C; Hadaschik BA; Kainthan RK; Brooks DE; So AI; Gleave ME; Burt HM
BJU Int; 2009 Apr; 103(7):978-86. PubMed ID: 19007363
[TBL] [Abstract][Full Text] [Related]
31. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of taxoids 5. Synthesis and evaluation of novel water-soluble prodrugs of a 3'-desphenyl-3'-cyclopropyl analogue of docetaxel.
Yamaguchi T; Harada N; Ozaki K; Arakawa H; Oda K; Nakanishi N; Tsujihara K; Hashiyama T
Bioorg Med Chem Lett; 1999 Jun; 9(12):1639-44. PubMed ID: 10397492
[TBL] [Abstract][Full Text] [Related]
33. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
34. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis.
Nornoo AO; Osborne DW; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):108-16. PubMed ID: 17869459
[TBL] [Abstract][Full Text] [Related]
35. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
[TBL] [Abstract][Full Text] [Related]
36. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
Fujimoto S
Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
[TBL] [Abstract][Full Text] [Related]
37. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
[TBL] [Abstract][Full Text] [Related]
38. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.
Greenwald RB; Pendri A; Conover CD; Zhao H; Choe YH; Martinez A; Shum K; Guan S
J Med Chem; 1999 Sep; 42(18):3657-67. PubMed ID: 10479297
[TBL] [Abstract][Full Text] [Related]
39. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer.
Xie Z; Guan H; Chen X; Lu C; Chen L; Hu X; Shi Q; Jing X
J Control Release; 2007 Feb; 117(2):210-6. PubMed ID: 17188776
[TBL] [Abstract][Full Text] [Related]
40. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]